Cabergoline
In brief
- Cabergoline is prescription-only in most countries and should normally be obtained from a pharmacy with a valid prescription; while some suppliers or pharmacies (including certain online vendors) may offer it without a receipt, purchasing or using cabergoline without medical supervision is not recommended and may be illegal or unsafe.
- Cabergoline is a dopamine agonist used primarily to treat hyperprolactinaemic disorders (for example prolactinomas) by stimulating D2 dopamine receptors in the pituitary to suppress prolactin secretion; it is also used as an adjunct in some cases of Parkinson’s disease.
- Typical regimens start at 0.25 mg twice weekly for hyperprolactinaemia with gradual titration (commonly to 0.5–1 mg per week; some patients require higher doses up to 1–2 mg/week or rarely more); for Parkinson’s adjunctive use dosing is individualised (for example starting 0.5 mg daily and titrating slowly).
- Administered orally as tablets (commonly 0.25 mg, 0.5 mg or 1 mg), usually taken with or without food according to the prescriber’s instructions.
- Biochemical reduction in prolactin is often seen within 48 hours, while clinical symptom improvement may take days to several weeks.
- Cabergoline has a long duration of action (long half-life, often allowing twice-weekly dosing); pharmacological effects can persist for several days to a week after a dose.
- Avoid or limit alcohol while taking cabergoline, as alcohol can increase dizziness, sedation and the risk of orthostatic hypotension.
- The most common side effect is nausea; other frequent effects include headache, dizziness, constipation, fatigue and orthostatic hypotension.
- Would you like to try cabergoline without a prescription?
Market Realities And Patient Experiences
Basic Cabergoline Information
- INN (International Nonproprietary Name): Cabergoline.
- Brand Names Available In United Kingdom: not specified.
- ATC Code: G02CB03.
- Forms & Dosages: Tablets 0.25 mg, 0.5 mg, 1 mg in blister or strip packs (2–8 ct) are listed.
- Manufacturers In United Kingdom: not specified.
- Registration Status In United Kingdom: not specified.
- OTC / Rx Classification: Prescription only (Rx) in all jurisdictions.
Access, Cost And Typical Patient Stories
How easy is it for people to get cabergoline and what do patients say about it?
Cabergoline is seen in community pharmacies as a specialist prescription-only medicine with limited general familiarity among patients.
Most prescriptions in the UK come via NHS endocrinology clinics following specialist assessment.
Patients commonly report rapid symptom relief such as reduced galactorrhoea, restored menses and improved libido after starting treatment.
Reviews and patient stories also show variability in tolerability, with nausea, dizziness and sleep changes often mentioned.
Pharmacies report that generics form the bulk of sales and that occasional stock-outs happen with particular brands or strengths.
Private prescriptions and online pharmacies increasingly handle urgent repeats and out-of-hours requests.
For product pages, a visual block or a patient-quote carousel is recommended to present real-world patient experience clearly.
Pharmacy teams should note that cabergoline remains prescription-only across jurisdictions and is supplied in multiple brands and strengths globally such as 0.25 mg, 0.5 mg and 1 mg tablets.
When discussing cost, emphasise that most UK patients receive supply via NHS prescriptions, while private patients may face wider price variation.
Include clear links on product pages for patients to request repeats or contact pharmacy clinicians for supply issues.
Product Snapshot For Pharmacy Product Page
Essential Product Facts Customers Need Up Front
What should customers see first when they land on a cabergoline product page?
| Item | Details |
|---|---|
| INN | Cabergoline |
| ATC | G02CB03 |
| Forms | Tablets: 0.25 mg, 0.5 mg, 1 mg |
| Prescription Status | Prescription-only (Rx) |
| Typical Pack Types | Blister or strip packs, typically 2–8 count |
Display clear brand and country packaging details where available.
Examples from international markets include Actavis ACT Cabergoline 0.5 mg and 1 mg in Canada, multiple EU brands such as Cabergolin 1 A Pharma or Cabergolina Teva, and Indian strip packs in 0.25–1 mg strengths.
Present a simple dosing visual for consumer clarity showing start dose, typical dose and maximum dose.
| Start Dose | Typical Dose | Max Dose |
|---|---|---|
| 0.25 mg twice weekly (hyperprolactinaemia) | Low weekly dose adjusted to effect | Up to 1–2 mg per week (rarely up to 4.5 mg/week) |
State MHRA-approved status and NHS prescribing pathways for UK customers where verification is available.
Make sure the product-information table includes brand, strength and pack size per the manufacturer data to avoid confusion at dispensing.
Indications And How UK Prescribers Use It
Clinical Uses, NHS Routes And Private Prescribing
What conditions is cabergoline used for and how will patients usually be started on it in the UK?
Cabergoline is primarily indicated for hyperprolactinaemic disorders such as prolactinomas and pituitary adenomas.
It is also used less commonly as an adjunct in Parkinson’s disease.
On the NHS, treatment is typically initiated in endocrinology following specialist review, with GPs taking on shared-care in some areas.
Private clinics may initiate treatment and arrange shared-care agreements with local prescribers.
MHRA and EMA guidance requires cabergoline to be prescription-only; prescribers should follow local formularies for initiation and follow-up.
| Indication | Typical Starting Dose | Typical Maintenance Dose |
|---|---|---|
| Hyperprolactinaemia | 0.25 mg twice weekly | Titrated by 0.25 mg twice weekly every 4 weeks to normalise prolactin or tolerability |
| Parkinson’s Disease (Adjunct) | 0.5 mg daily | Individualised, titrated slowly |
Prescribers monitor prolactin and clinical response and may continue therapy long term if needed.
Explain clearly to patients that initiation usually follows endocrine assessment, imaging where indicated, and baseline blood tests.
Mechanism Of Action — Practical Explanation For Patients
What It Does And Why It Matters Clinically
How does cabergoline lower prolactin and what do patients gain from that effect?
Cabergoline is a dopamine D2 receptor agonist that suppresses pituitary prolactin secretion.
Lowering prolactin reduces galactorrhoea and can restore normal menstrual cycles and ovulation in women.
Restoration of normal prolactin levels can also improve libido and sexual function in men and women.
In patients with prolactin-secreting tumours, cabergoline can reduce tumour size and related symptoms.
For Parkinson’s disease, cabergoline’s dopamine stimulation supports motor pathways, but this is a less common indication.
Display a simple diagram on the product page showing: Dopamine → D2 Receptor → Decreased Prolactin.
Dosage Regimens, Titration And Practical Dosing Tips
Real-World Regimens And Safety-First Titration
What dosing patterns do clinicians use and how should patients take cabergoline safely?
For hyperprolactinaemia the usual starting regimen is 0.25 mg twice weekly, increasing by 0.25 mg twice weekly every four weeks as needed.
Maintenance doses are frequently low and tailored to prolactin levels and symptoms.
Parkinson’s regimens begin with low daily dosing such as 0.5 mg daily and are titrated cautiously.
Maximum weekly doses can be up to 1–2 mg per week in most cases, with rare situations reported up to 4.5 mg per week.
| Scenario | Usual Starting Dose | Titration Guidance |
|---|---|---|
| Hyperprolactinaemia | 0.25 mg twice weekly | Increase by 0.25 mg twice weekly every 4 weeks until target achieved |
| Parkinson’s Adjunct | 0.5 mg daily | Titrate slowly per neurologist guidance |
Checklist for patients: do not double doses, take with food if nausea occurs, and if a dose is missed take it when remembered unless close to the next dose.
Elderly patients should start at lower doses and titrate slower to reduce risk of orthostatic hypotension and psychiatric side effects.
Children are not recommended to use cabergoline due to lack of established safety data.
Contraindications And High‑Risk Groups
Absolute And Relative Contraindications To Screen For
Who must not take cabergoline and who needs extra monitoring?
Absolute contraindications include uncontrolled hypertension, known hypersensitivity to cabergoline or ergot derivatives, and a history of fibrotic disorders such as pulmonary or cardiac valvular fibrosis.
Pregnancy is an absolute contraindication unless benefits clearly outweigh risks and a specialist advises continuation.
Relative cautions include existing cardiac or valvular disease, severe hepatic impairment and severe renal impairment requiring close review.
Patients with a history of psychiatric disorders require careful assessment and monitoring for behavioural changes.
- Ask about known heart valve disease or breathlessness when screening.
- Obtain baseline echocardiography if prolonged therapy is planned or if there are cardiac concerns.
- Advise women of childbearing potential to discuss pregnancy intentions before starting treatment.
Side Effects, Monitoring And Patient Counselling
Practical Counselling Points At Dispensing
What should patients be warned about and what monitoring is needed?
Common side effects include nausea, headache, constipation, dizziness, fatigue and abdominal discomfort.
More significant issues reported include orthostatic hypotension, sleep disturbances, peripheral oedema and depressive symptoms.
Patients should be advised to report mood changes, hallucinations or any new impulse-control behaviours promptly.
| Frequency | Adverse Reactions |
|---|---|
| Mild | Nausea, headache, constipation, fatigue, dizziness |
| Moderate | Orthostatic hypotension, sleep disturbance, peripheral oedema, depression |
Recommend baseline blood tests such as prolactin and renal/hepatic profile and periodic prolactin checks during therapy.
Consider baseline and periodic echocardiography for patients on prolonged high-dose therapy to screen for valvular changes.
Counselling script at dispensing: take with food if you feel sick, avoid driving until you know how cabergoline affects you, and rise slowly from sitting to reduce dizziness.
Provide a warning panel for urgent symptoms such as breathlessness, chest pain, sudden swelling or new psychiatric symptoms and advise immediate medical contact if these occur.
Drug Interactions And Medicines To Avoid
Practical Interaction Checks At Dispensing
Which medicines reduce effect or increase risk when given with cabergoline?
Dopamine antagonists such as many antipsychotics and metoclopramide can reduce cabergoline’s efficacy and should be reviewed before starting treatment.
Concurrent antihypertensive therapy may increase the risk of orthostatic hypotension when cabergoline is initiated or doses are increased.
Ergot derivatives may add to adverse effect burden and should be avoided where possible.
Check for medicines that heavily affect hepatic metabolism and agents known to prolong QT as part of routine BNF/MHRA screening.
Provide a short interaction checklist for pharmacy staff: review antipsychotics, antiemetics, antihypertensives and other dopamine agonists before dispensing.
Clinical Comparisons: Cabergoline Versus Bromocriptine And Quinagolide
Choice Drivers For Clinicians And Patients
How do clinicians decide between cabergoline, bromocriptine and quinagolide?
Cabergoline is often preferred because it has a longer half-life allowing less frequent dosing and generally better gastrointestinal tolerability compared with bromocriptine.
Bromocriptine may still be chosen in pregnancy planning due to a longer history of use in that setting.
Quinagolide is an alternative in some European settings and may be used where cabergoline is not available or suitable.
| Agent | Dosing Frequency | Tolerability | Cost/Notes |
|---|---|---|---|
| Cabergoline | Twice weekly or low weekly dose | Better GI tolerability | Often preferred; generics widely available |
| Bromocriptine | Multiple daily doses | More GI side effects | Historical safety data in pregnancy |
| Quinagolide | Daily | Alternative option in Europe | Use where available |
When advising patients, include comparative points on frequency, likely tolerability and monitoring needs.
Sourcing, Brands, Generics And Supply Chain Notes
Brands Available And What Pharmacies Should Stock
What brands exist and which strengths are most useful for stock management?
Major manufacturers and brands listed in international data include Teva, Sandoz, Sun Pharma, Cipla, Aurobindo, 1A Pharma, Actavis and more.
Common pack sizes are small blister packs of 2–8 tablets in strengths 0.25 mg, 0.5 mg and 1 mg.
For UK retail pharmacies, stocking 0.5 mg is sensible because it is commonly used and covers many titration steps.
APIs and finished products often originate from India, China and other international suppliers, which can lead to short-term shortages for specific brands or strengths.
| Manufacturer / Brand | Typical Strengths | Notes |
|---|---|---|
| Teva | 0.5 mg | Listed in multiple markets |
| Actavis | 0.5 mg, 1 mg | Manufactured for Canada listings |
| Sun Pharma / Cipla / Aurobindo | 0.25–1 mg | Common in Indian market and global generics |
Online UK-registered pharmacies and high-street chains fulfil repeats and e-prescriptions, but ensure valid prescription verification before supply.
Pharmacy Dispensing Checklist And Labelling
Essential Cues And Patient Information Leaflets
What must a pharmacist check and what should be on the label and leaflet?
- Confirm the indication and that the prescription is valid for cabergoline.
- Check pregnancy status when relevant and advise pregnancy avoidance unless directed by a specialist.
- Advise on orthostatic risk and provide a written dosing schedule.
- Supply a warning sheet for psychiatric symptoms and impulse-control changes.
Label suggestions include “Prescription-only medicine” and “Do not drive if dizzy”.
Advise storage below 25°C and handing over the patient information leaflet with clear missed-dose and overdose advice.
Provide standard SNOMED or pharmacy filing codes as per local practice for audit and repeat dispensing records.
Storage, Packaging And Transport Guidance
Practical Instructions For Patients And Pharmacies
How should cabergoline be stored and transported both in pharmacy and for delivery?
Store below 25°C in original packaging to protect from moisture and light.
Check blister integrity and expiry on receipt into stock and before dispensing.
Avoid freezing and avoid exposing packs to direct sunlight or high humidity.
For online fulfilment use temperature-stable tracked shipping and tamper-evident packaging to protect product integrity during transit.
On product pages include a clear visual such as “Do Not Refrigerate / Keep Dry / Store Below 25°C”.
Legal, Prescribing And Reimbursement Landscape In The United Kingdom
NHS Vs Private Prescriptions And E‑Prescribing Realities
What do patients need to know about how cabergoline is prescribed and paid for in the UK?
Cabergoline is prescription-only and MHRA-regulated for licensed uses although specific UK registration details are handled by the regulator and local formularies.
On the NHS, endocrine disorders are routinely managed with prescriptions; regional differences exist in prescription charges and exemptions across the UK.
Remember that prescriptions are free in Scotland, Wales and Northern Ireland for many patients, while England uses the standard NHS prescription charge unless exempt.
Electronic prescriptions and NHS repeat dispensing are common and community pharmacies often fulfil eRD and e-prescriptions for ongoing supplies.
Private prescriptions and online pharmacy fulfilment require valid paper or electronic prescriptions and appropriate clinical verification before supply.
Cabergoline is not a controlled drug, but good stock control and safe storage are still required in practice.
Practical FAQs And Purchase Workflow For Product Page
Buying, Repeats, Returns And Emergency Advice
What questions do customers ask and how does the ordering process work?
- Can I buy cabergoline without a prescription? No. Cabergoline is a prescription-only medicine and requires a valid prescription for supply.
- What if I miss a dose? Take the dose when you remember unless it is close to the next scheduled dose. Do not double up doses.
- What to do in case of overdose? Seek urgent medical attention. Symptoms may include nausea, vomiting, hallucinations and low blood pressure.
- How are repeats handled? Upload your prescription for pharmacist verification and set up repeat dispensing where eligible via NHS e-prescriptions or private repeat services.
- What is the returns policy? Return unopened packs within the stated time frame according to pharmacy policy; dispense-used packs cannot be returned for safety reasons.
Ordering workflow: upload a valid prescription, pharmacist completes clinical verification, choose delivery or collection, and receive confirmation once dispatched.
In our online pharmacy, cabergoline is supplied on presentation of a valid prescription, with discreet delivery to the United Kingdom in 5–14 days.
For emergencies or if patients experience severe adverse effects, advise immediate contact with emergency services or the prescriber.
Delivery Across United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 5-7 days |
| Birmingham | England | 5-7 days |
| Manchester | England | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Leeds | England | 5-7 days |
| Liverpool | England | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Bristol | England | 5-7 days |
| Sheffield | England | 5-7 days |
| Newcastle Upon Tyne | England | 5-7 days |
| Cardiff | Wales | 5-7 days |
| Belfast | Northern Ireland | 5-7 days |
| Norwich | England | 5-9 days |
| Plymouth | England | 5-9 days |
| Leicester | England | 5-9 days |
Final Notes For Pharmacy Teams
Practical Reminders
Keep a clear, up-to-date product page with brand, strength and pack size information to minimise dispensing errors.
Train staff to screen for contraindications such as uncontrolled hypertension and fibrotic disease at point of supply.
Provide patients with concise written dosing schedules, monitoring plans and emergency contact instructions.
Maintain contact routes with local endocrine teams for shared-care queries and to manage supply interruptions promptly.
When in doubt, refer to the original product monograph or the prescriber for patient-specific dose adjustments and monitoring plans.
